Physician profile
Daniel Camp
NPI 1215325576
$2,424.11
in general payments reported to CMS, 2019-2025
16 companies · $281 in 2025
The $281 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $934 · 2022: $421 · 2023: $552 · 2024: $237 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,069.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,069.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $895.84 | 2021-2025 | |
| Lensar, INC. | $650.45 | 2021 | |
| Pfizer INC. | $160.46 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $133.15 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $118.55 | 2021-2023 | Ajovy |
| Lilly USA, LLC | $97.06 | 2021-2024 | Emgality, Reyvow |
| Biohaven Pharmaceuticals, INC. | $81.68 | 2021 | |
| Upsher-Smith Laboratories LLC | $74.45 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $52.33 | 2022-2023 | Quviviq |
| Impel Pharmaceuticals INC. | $38.43 | 2023 | Trudhesa |
| Amgen INC. | $24.96 | 2021-2022 | |
| Merz Pharmaceuticals, LLC | $22.49 | 2025 | Xeomin |
| Otsuka America Pharmaceutical, INC. | $21.94 | 2024 | Rexulti |
| Lundbeck LLC | $20.18 | 2025 | Vyepti |
| Bioventus LLC | $16.68 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $15.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Camp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.